Compare AbCellera Biologics Inc (ABCL) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Wendys Co — how do they compare? AbCellera Biologics Inc trades at $10.19 (market cap $2.99B), while Wendys Co trades at $8.5 (market cap $1.44B). The key difference: AbCellera Biologics Inc is far larger — about 2.1× Wendys Co's market cap, and Wendys Co pays a 3.71% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | WEN | |
|---|---|---|
Market Cap | $2.99B | $1.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $9.76 | $10.68 |
52-Week Low | $2.78 | $6.17 |
Enterprise Value | $2.58B | $5.17B |
Dividend Yield | — | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.
The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.
WEN trades at $8.595, up 17.74% in 24 hours, with a neutral technical signal. Recent Q2 2026 EPS of $0.18 beat expectations, but revenue trends are flat and net income margin declined to 5.72% in 2025. The company cut its dividend and withdrew 2026 guidance amid a strategic turnaround under new leadership, facing traffic declines and loss of its No. 2 U.S. burger chain position to Burger King.
Outlook is cautious; the dividend cut frees cash for restructuring, but execution risks are high. Valuation appears reasonable with a P/E of 11.44, though high debt and competitive pressures pose significant headwinds. Analyst consensus is mixed, with 62.75% hold ratings reflecting uncertainty around the turnaround plan's success.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
